Cytovale Receives Additional BARDA Funding to Evaluate Rapid Sepsis Diagnostic in Persons Under Investigation (PUI) for COVID-19
Apr 23, 2020•about 5 years ago
Description
Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, announced today the expansion of a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to conduct a pilot study for Cytovale’s Rapid Sepsis Diagnostic System for patients with potential respiratory infections, including those with SARS-CoV-2, responsible for COVID-19.